mRNA Therapeutics CDMO Market Report 2026

mRNA Therapeutics CDMO Market Overview

• mRNA Therapeutics CDMO market size has reached to $4.74 billion in 2025 • Expected to grow to $8.26 billion in 2030 at a compound annual growth rate (CAGR) of 11.7% • Growth Driver: The Growing Burden Of Chronic And Infectious Diseases Fueling The Market Due To Increasing Therapeutic Demand • Market Trend: Advancing mRNA Vaccines With In Situ Nanomedicine For Targeted Immunity • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

The key promising market opportunities in the mrna therapeutics cdmo market include: • Biotechnology Companies (Segmentation By End User) → Expected gain of $2564.92 Million • Manufacturing Services (Segmentation By Type Of Service) → Expected gain of $2000.38 Million • Cancer Immunotherapies (Segmentation By Application) → Expected gain of $1411.7 Million

What Is Covered Under mRNA Therapeutics CDMO Market?

An mRNA therapeutics CDMO, or messenger ribonucleic acid therapeutics contract development and manufacturing organization, is a specialized third-party entity that provides end-to-end support for the research, development, and scalable production of mRNA-based therapeutic agents under contractual arrangements with pharmaceutical or biotechnology companies. These organizations play a critical role in accelerating time-to-market, ensuring regulatory compliance, and enabling flexible capacity for mRNA therapeutic pipelines. The main types of services in the mRNA therapeutics CDMO are development services, manufacturing services, and laboratory services. Development services of mRNA therapeutics CDMO refers to the end-to-end support provided for the design, optimization, and scale-up of mRNA-based therapeutics, including synthesis, formulation, analytical development, and process development tailored to client-specific product requirements. These therapeutics are used in the indications including infectious diseases, metabolic and genetic diseases, and cardiovascular and cerebrovascular diseases in applications such as viral vaccines, protein replacement therapies, and cancer immunotherapies used by the end users, including pharmaceutical companies, biotechnology companies, academic institutions, and research organizations.

What Is The mRNA Therapeutics CDMO Market Growth Forecast?

The mrna therapeutics cdmo market size is expected to see rapid growth in the next few years. It will grow to $8.26 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to rising investment in mrna therapeutics pipelines, technological advancements in plasmid dna and mrna synthesis, growth of cancer immunotherapy and protein replacement therapies, increasing demand for fill-finish services, expansion of partnerships between biotechs and cdmos. Major trends in the forecast period include rising demand for outsourced mrna development and manufacturing, increasing focus on lipid nanoparticle (lnp) formulation technologies, expansion of viral vaccine and cancer immunotherapy pipelines, enhanced regulatory compliance and quality assurance measures, growing adoption of analytical and bioanalytical laboratory services.

What Is The Driver Of The mRNA Therapeutics CDMO Market?

The growing burden of chronic and infectious diseases is expected to propel the growth of the mRNA therapeutics CDMO market going forward. Chronic and infectious diseases encompass long-term health conditions such as diabetes, cardiovascular disorders, and asthma, as well as illnesses caused by pathogenic microorganisms, including viruses, bacteria, and parasites, which can spread directly or indirectly among individuals. Chronic and infectious diseases are increasing due to aging populations, which are more susceptible to both long-term illnesses and infections. mRNA therapeutics CDMO helps address chronic and infectious diseases by providing end-to-end development and manufacturing services that accelerate the delivery of targeted, personalized mRNA therapies to patients. For instance, in October 2024, according to the World Health Organization, a Switzerland-based international public health organization, approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, up from about 7.5 million in 2022, highlighting the escalating burden of infectious diseases globally. Therefore, the growing burden of chronic and infectious diseases is driving the growth of the mRNA therapeutics CDMO industry.

How Will The Drivers Impact Growth In The Global mRNA Therapeutics CDMO Market?

• Growth In Multi-Valent And Combination mRNA Vaccines (Medium) – During the forecast period, the growth in multi-valent and combination mrna vaccines is expected to propel the growth of the mrna therapeutics cdmo market in the forecast period. drug developers are increasingly designing vaccines that target multiple pathogens or variants in a single product to enhance protection and streamline immunization programs. these advanced formulations involve greater manufacturing complexity, higher regulatory standards, and sophisticated delivery technologies, which many companies prefer to outsource. cdmos offering end-to-end mrna services, including sequence design, lipid nanoparticle formulation, large-scale production, and fill-finish operations, are well positioned to benefit. as clinical pipelines broaden and commercialization accelerates, demand for specialized cdmo partners is projected to rise significantly across global markets. therefore, the growth in multi-valent and combination mrna vaccines will drive the growth of the mrna therapeutics cdmo market. the growth in growth in multi-valent and combination mrna vaccines growth contribution during the forecast period in 2025 is 1.5%. • Increasing Outsourcing Of Late-Stage And Commercial Manufacturing (Medium) – During forecast period, the increasing outsourcing of late-stage and commercial manufacturing is expected to propel the growth of the mRNA therapeutics CDMO market. As more mRNA candidates progress into Phase III trials and reach regulatory approval, companies require large-scale, compliant production capabilities that involve high capital investment and technical expertise. Rather than building in-house infrastructure, many developers are partnering with specialized CDMOs to reduce costs, accelerate time to market, and manage regulatory complexity. CDMOs provide validated manufacturing platforms, quality assurance systems, and global supply capabilities. This shift toward strategic outsourcing is increasing long-term manufacturing contracts, capacity expansion, and revenue opportunities across the mRNA CDMO industry. Therefore, the increasing outsourcing of late-stage and commercial manufacturing will drive the growth of the mRNA therapeutics CDMO market. The growth in increasing outsourcing of late-stage and commercial manufacturing contribution during the forecast period in 2025 is 1.0%. • Venture Capital And Pharma Investment In RNA (Low) – During the forecast period, the venture capital and pharma investment in rna is expected to propel the growth of the mrna therapeutics cdmo market in the forecast period. substantial financial backing is enabling biotech startups and established drug companies to expand research pipelines, accelerate clinical development, and advance more mrna candidates toward commercialization. as development activity intensifies, the need for specialized manufacturing, process optimization, and regulatory-compliant production continues to grow. many companies rely on cdmos to provide scalable infrastructure and technical expertise without heavy upfront capital expenditure. this steady flow of investment is therefore translating into higher outsourcing demand, long-term manufacturing partnerships, and sustained revenue growth for mrna-focused cdmos worldwide. therefore, the venture capital and pharma investment in rna will drive the growth of the mrna therapeutics cdmo market. the growth in venture capital and pharma investment in rna growth contribution during the forecast period in 2025 is 0.8%. • Growing Trend Of Pharma-CDMO Partnerships (Low) – During forecast period, the growing trend of pharma-CDMO partnerships is expected to propel the growth of the mRNA therapeutics CDMO market. Drug developers are collaborating with specialized CDMOs to access advanced mRNA manufacturing platforms, technical expertise, and scalable production capacity. These partnerships help reduce development risks, shorten timelines, and optimize costs while ensuring regulatory compliance and consistent product quality. In many cases, long-term agreements cover clinical development through commercial supply, providing stable revenue streams for CDMOs. As mRNA pipelines continue to expand across vaccines and therapeutics, such collaborative models are becoming a preferred approach. Therefore, the growing trend of pharma-CDMO partnerships will drive the growth of the mRNA therapeutics CDMO market. The growth in growing trend of pharma-CDMO partnerships growth contribution during the forecast period in 2025 is 0.5%.

How Will The Restraints Impact Growth In The Global mRNA Therapeutics CDMO Market?

• Instability And Degradation Of RNA Targets (Medium) – During the forecast period, instability and degradation of rna targets is expected to hinder the growth of the mrna therapeutics cdmo market in forecast period. mrna is highly sensitive to temperature, enzymes, and environmental conditions, requiring strict cold-chain logistics, specialized storage, and advanced formulation technologies to maintain product integrity. these challenges increase manufacturing complexity, operational costs, and the risk of product loss during production and distribution. for some developers, these technical barriers can delay development timelines or limit large-scale commercialization. cdmos must invest heavily in stabilization technologies, quality controls, and infrastructure, which may constrain capacity expansion and profitability. therefore, stability and degradation of rna targets may hinder the growth of the mrna therapeutics cdmo market. growth affected by instability and degradation of rna targets during the forecast period in 2025 is -2.0%. • Complexity Of RNA-Based Drug Discovery (Medium) – During the forecast period, complexity of RNA-based drug discovery is expected to hinder the growth of the mRNA therapeutics CDMO market. Designing stable, effective mRNA sequences requires advanced bioinformatics, delivery technologies, and extensive optimization to achieve targeted protein expression while minimizing immune reactions. These challenges often result in longer development timelines, higher failure rates, and increased research costs. For many biotech companies, the steep learning curve can slow pipeline progress and reduce the number of candidates advancing to clinical and commercial stages. As a result, demand for large-scale manufacturing services may grow more gradually, temporarily constraining outsourcing volumes and revenue expansion for mRNA-focused CDMOs. Therefore, complexity of RNA-based drug discovery may hinder the growth of the mRNA therapeutics CDMO market. Growth affected by complexity of RNA-based drug discovery during the forecast period in 2025 is -1.5%. • Trade War And Tariffs (Low) – During the forecast period, trade wars and tariffs are expected to restrain the growth of the mrna therapeutics cdmo market during the forecast period by increasing the costs of imported raw materials, specialized enzymes, nucleotides, lipid nanoparticles, bioprocessing equipment, single-use systems, and cold-chain infrastructure, as well as advanced manufacturing technologies and quality control tools required for large-scale mrna production, formulation, and commercialization. many cdmos rely on imported raw materials such as nucleotides, enzymes, lipid components, and specialized bioprocessing equipment sourced from global suppliers. higher tariffs can raise production expenses, reduce profit margins, and make large-scale manufacturing less cost-effective for both cdmos and their clients. in addition, trade restrictions may disrupt supply chains, delay project timelines, and limit access to advanced technologies. therefore, trade wars and tariffs may restrain the growth of the mrna therapeutics cdmo market. growth affected by trade wars and tariffs during the forecast period in 2025 is -0.3%.

Key Players In The Global mRNA Therapeutics CDMO Market

Major companies operating in the mrna therapeutics cdmo market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, FUJIFILM Holdings Corporation, Evonik Industries AG, AGC Biologics GmbH, Eurofins Scientific SA, Samsung Biologics Co. Ltd., Wuxi Biologics, Recipharm AB, EMERGENT BioSolutions Inc., Genscript Biotech, Ginkgo Bioworks Holdings Inc., Corden Pharma Corp., TriLink BioTechnologies LLC, Biocina Pty Ltd., Aldevron LLC, Synbio Technologies LLC, etherna manufacturing, Bio-Synthesis Inc., Biomay AG.

Global mRNA Therapeutics CDMO Market Trends and Insights

Major companies operating in the mRNA therapeutics CDMO market are focusing on developing innovative solutions, such as in situ nanomedicine vaccines, to enhance the effectiveness and precision of mRNA-based vaccines through targeted immune stimulation. An in situ nanomedicine vaccine is a next-generation mRNA-based therapeutic designed to generate nanomedicines within the patient’s body, enabling targeted delivery and customized immune activation through engineered transgene expression. For instance, in January 2025, Esphera SynBio Inc., a Canada-based biotechnology company, launched a new project supported by the CQDM Quantum Leap program. The initiative aims to enhance first-generation lipid nanoparticle or messenger RNA (LNP/mRNA) vaccines by incorporating proprietary transgene designs that induce in vivo production of immunostimulatory nanomedicines. This approach enables precise antigen delivery and tailored immune responses, positioning the technology as a potential breakthrough in vaccine innovation.

What Are Latest Mergers And Acquisitions In The mRNA Therapeutics CDMO Market?

In September 2024, Agilent Technologies Inc., a US-based medical equipment company, acquired BIOVECTRA for $0.925 billion. This deal aims to expand Agilent’s CDMO capabilities into high-growth modalities, including mRNA therapeutics, by adding BIOVECTRA’s expertise in biologics and advanced pharmaceutical manufacturing. BIOVECTRA is a Canada-based contract development and manufacturing organization specializing in mRNA therapeutics and other modalities.

What Defines the mRNA Therapeutics CDMO Market?

The mRNA therapeutics CDMO market consists of revenues earned by entities by providing services such as supply chain management, cold chain logistics, quality assurance auditing, clinical trial material preparation, batch release testing, serialization, and packaging. The market value includes the value of related goods sold by the service provider or included within the service offering. The mRNA therapeutics CDMO market also includes sales of products such as lipid excipients, nucleotide reagents, capping analogs, custom RNA oligonucleotides, and modified nucleosides. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the mRNA Therapeutics CDMO Market Report 2026?

The mrna therapeutics cdmo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the mrna therapeutics cdmo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.